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Cells by Tyrosinase Haptenation and Melanosome
Autophagy
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Cornelis J.M. Melief4 and Rosalie M. Luiten1
In this study, we report the previously unknown mechanism of inducing robust anti-melanoma immunity by the
vitiligo-inducing compound monobenzone. We show monobenzone to increase melanocyte and melanoma
cell immunogenicity by forming quinone-haptens to the tyrosinase protein and by inducing the release of
tyrosinase- and melanoma antigen recognized by T cells-1 (MART-1)-containing CD63þ exosomes following
melanosome oxidative stress induction. Monobenzone further augments the processing and shedding of
melanocyte-differentiation antigens by inducing melanosome autophagy and enhanced tyrosinase ubiquitination,
ultimately activating dendritic cells, which induced cytotoxic human melanoma-reactive T cells. These T cells
effectively eradicate melanoma in vivo, as we have reported previously. Monobenzone thereby represents a
promising and readily applicable compound for immunotherapy in melanoma patients.
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INTRODUCTION
In 1939, Oliver et al. discovered that monobenzone is a
powerful inducer of leukoderma (Oliver et al., 1939). Clinical
monobenzone studies report skin sensitization (Lyon and
Beck, 1998) and spreading of depigmentation beyond the
skin application site, suggesting a systemic reaction (Mosher
et al., 1977). In healthy people who apply monobenzone to
acquire a lightened skin tone, it can induce depigmentation
that is clinically and histologically indistinguishable from
vitiligo (Grojean et al., 1982). Importantly, vitiligo patients
using monobenzone to achieve complete depigmentation
often experience an application-related dermatitis exclusively
in pigmented areas of skin (Nordlund et al., 1985), indicating
its dependence on melanocytes. Nevertheless, the working
mechanism of monobenzone was unknown. Studies on the
structurally related, less potent skin-depigmenting agent
4-methoxyphenol show that this compound is converted into
a reactive benzoquinone product by the enzyme tyrosinase
(Nair et al., 1993) present in the melanosomes of skin
melanocytes. Benzoquinone forms haptens to cysteine
residues in proteins (Naish et al., 1988), and was thereby
identified as a skin sensitizer (Nazih et al., 1993). Further-
more, animal studies demonstrated that the depigmenting
action of phenols or catechols largely depends on their
conversion by tyrosinase, and the subsequent formation of
benzoquinone-haptens to proteins (Menter et al., 1993).
Indeed, the resulting quinone metabolites induced more
profound depigmentation than their parental compounds
(Tayama and Takahama, 2002).
Vitiligo is mediated by the progressive autoimmune
destruction of skin melanocytes by CD8þ T cells (van den
Boorn et al., 2009). Furthermore, we have reported previously
that by initiating specific autoimmunity against pigmented
cells, monobenzone-based immunotherapy effectively inhi-
bits the growth of murine melanoma in vivo (van den Boorn
et al., 2010). This discovery has provided pivotal in vivo
data for us to embark on the present study, in which
we investigated the cellular mechanisms by which mono-
benzone induces the systemic CD8þ T-cell response that
specifically kills pigmented cells, following its selective
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interaction with the enzyme tyrosinase in exposed pigmented
cells. Our present study shows that monobenzone confers
potent immunogenicity to exposed pigmented cells via the
generation of quinone-haptens, melanosome autophagy, and
the secretion of melanocyte antigen-containing exosomes in
response to monobenzone-induced reactive oxygen species
(ROS). We also found these processes to activate dendritic
cells (DCs), which prime robust T-cell immunity against
melanoma cells.
RESULTS
Tyrosinase is inactivated by monobenzone through quinone-
hapten formation
Being an alternative substrate, monobenzone inactivates the
pigment-synthesis enzyme tyrosinase (Naish et al., 1988). To
investigate this process, we performed spectrophotometry
studies with mushroom tyrosinase. Figure 1a shows the
conversion of its natural substrate L-3,4-dihydroxyphenyl-
alanine (L-DOPA) into dopachrome (Mason, 1948), with the
autoconversion of dopachrome into 5,6-dihydroxyindole
(Aroca et al., 1991). The interaction between tyrosinase and
monobenzone revealed the formation of covalent quinone–-
cysteine bonds (quinone-haptens) (Hay et al., 2004) and the
reduction of the tyrosinase enzyme (Martin et al., 1981). This
suggests that quinone-haptens formed by the monobenzone
metabolite 4-benzoxy-1,2-benzoquinon (Figure 1b) reduce
and inactivate the enzyme. Incubation of tyrosinase with a
higher concentration of monobenzone completely inacti-
vated the enzyme, as no dopachrome was produced in
response to L-3,4-dihydroxyphenylalanine addition at the
plateau phase of the reaction. Importantly, this excludes
substrate competition between monobenzone and L-DOPA.
To test whether the monobenzone metabolite 4-benzoxy-
1,2-benzoquinon indeed binds cysteine residues within
peptides, we incubated various 9-mer peptides containing
0, 1, or 2 cysteine residues with synthetically prepared
4-benzoxy-1,2-benzoquinone. Peptides containing cysteine
were incubated with a 2-fold excess of the metabolite.
As a control, a peptide containing no cysteine residues
was incubated with an 8-fold quinone excess. The liquid
chromatography/mass spectrometry results are summarized
in Supplementary Table S1 online. The peptides contain-
ing cysteines both formed quinone-haptens, whereas the
control peptide did not display any quinone haptenation.
Collectively, these data reveal that the enzyme tyrosinase
is inactivated by monobenzone, likely by the formation of
quinone-haptens formed by the 4-benzoxy-1,2-benzoquinon
metabolite.
Cellular pigment synthesis is suppressed by monobenzone
To investigate the effect of monobenzone on melanogenesis,
we incubated human cutaneous melanoma cells and
normal human melanocytes with various concentrations of
monobenzone for 72 hours in vitro. Importantly, equal
numbers of viable cells were used for each experiment, to
exclude effects of divergent cell numbers on melanin
determinations. Melanin synthesis, induced in melanoma
cells by isobutylmethylxanthine and melanocyte-stimulating
hormone (a-MSH, Figure 1c), was significantly decreased
by monobenzone exposure in a dose-dependent manner.
Similarly, melanogenesis was suppressed by monobenzone
in normal human melanocytes, which appeared more
sensitive to inhibition.
On the basis of the hypothesis that high concentrations
of monobenzone can be selectively toxic to tyrosinase-
expressing pigment cells (Hariharan et al., 2009), we tested
the selective toxicity of monobenzone to pigmented cells
as compared with non-pigmented cells. The sensitivity
to monobenzone varied between cell lines but did not corre-
late to the presence of pigmentation (Figure 1d). Although
tyrosinase was reexpressed in the amelanotic tyrosinase-
negative melanoma cell line BLM (BLM-tyr), sensitivity to
monobenzone was not affected. Control experiments using
H2O2 showed a pigmentation-dependent resistance to oxida-
tive stress, as expected by the antioxidant effect of melanin
(Brenner and Hearing, 2008; Figure 1d). These data show that
the cytotoxicity of monobenzone is independent of the
pigmentation level or the presence of the tyrosinase enzyme.
Monobenzone induces melanosome degradation and autophagy
We studied the effects of monobenzone on melanosome
formation by electron microscopy, in analogy to the reported
disruption of melanosomes by the depigmenting compound
hydroquinone (Jimbow et al., 1974). Untreated melanoma
cells contained all four melanosome developmental stages
(Fitzpatrick et al., 1969) (Figure 2a), with cigar-like morpho-
logy and the typical striations of stage II and III melanosomes.
Exposing the melanoma cells to monobenzone for 60minutes
reduced the number of stage IV melanosomes in the
cytoplasm (Figure 2b). Closer examination revealed that the
melanosomes, especially stages II and III, were smaller and
appeared disorganized or ruptured (arrows). Prolonging
monobenzone exposure to 3 hours induced distinct cyto-
plasmic changes (Figure 2c). The cells no longer contained
stage IV melanosomes, and the stage III melanosomes were
unmelanized, indicating that monobenzone impeded mela-
nogenesis. Although overall cell morphology appeared
normal, structural changes characteristic of melanosome
macroautophagy were seen evidenced by electron-dense
matter enclosed in a double-membrane structure ofB500 nm
diameter, the hallmark of the autophagosome (Mizushima
et al., 2010; AP; Figure 2c, arrowheads for double
membrane). Moreover, APs fused with electron-lucent
lysosome-like vesicles (L; arrows for fusion sites), forming
characteristic single-membrane walled autolysosomes
(Mizushima, 2007). These results show that monobenzone
disturbs melanogenesis, and mediates the disruption and
subsequent autophagy of melanosomes, allowing enhanced
degradation of melanosomal proteins for antigen processing
(Dengjel et al., 2005).
Melanosome autophagy targets tyrosinase to major
histocompatibility complex class II compartments via lysosomal
degradation involving tyrosinase ubiquitination
Autophagy typically involves fusion of APs with lysosomes,
excludes endosome participation (Mizushima, 2007), and
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delivers antigen to major histocompatibility complex (MHC)
class II compartments (Schmid and Munz, 2007). We
identified the organelles with which the monobenzone-
induced AP fuses by confocal laser scanning microscopy. In
this study, we used the tyrosinase-specific T311-clone
monoclonal antibody (Chen et al., 1995) to detect melano-
somes, which specifically recognizes an immunodominant
linear tyrosinase determinant (tyrosinase233247) that can be
tracked beyond the protein degradation stage (Willers et al.,
2005).
Melanoma cells, but not MCF7 control cells (not shown),
selectively initiated a lysosomal degradation response on
1 hour of monobenzone exposure (Figure 3). Lysosome-
associated membrane protein-1 (LAMP1) expression was
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Figure 1. Quinone haptenation reduced melanogenesis, but not selective toxicity to pigmented cells by monobenzone. (a) Spectrophotometry showing
the reaction of L-3,4-dihydroxyphenylalanine (L-DOPA) or monobenzone with mushroom tyrosinase. Reaction kinetics are depicted for each experiment.
Left panels: tyrosinase converted L-DOPA (250mM) into dopachrome and 5,6-dihydroxyindole (DHI): 473- and 310/290nm absorption peaks, respectively.
Middle panels: covalent quinone–cysteine bonds were formed (260 nm peak) and tyrosinase was reduced (420 nm) on reacting with monobenzone. Right panels:
tyrosinase was inactivated by 300 mM monobenzone. No dopachrome or DHI formation was observed when 250 mM L-DOPA was added at t¼60minutes.
Data represent the results of five independent experiments. (b) Schematic overview of monobenzone conversion into 4-benzoxy-1,2-benzoquinon by tyrosinase.
The 4-benzoxy-1,2-benzoquinon can bind covalently to cysteine residues by nucleophilic attack of sulfhydryl groups. (c) Melanoma cells (136.2; left),
pigment synthesis stimulated conditions by isobutylmethylxanthine and melanocyte-stimulating hormone (I/M), or melanocytes (M0508; right) were incubated
with increasing concentrations of monobenzone. Graphs show a dose-dependent decrease of cellular melanin content. Both panels are representative of
two independent experiments. *Po0.05, **Po0.01, and ***Po0.0001 using paired t-test (95% confidence interval). Graphs depict mean with SEM. (d) Left
panel: pigmented (black symbols) or amelanotic (open symbols) human melanoma cells were incubated for 72 hours with monobenzone. Pigmented and
amelanotic melanoma cells showed variable survival in the presence of monobenzone, not correlating to cellular pigmentation. Expression of tyrosinase enzyme
in the amelanotic melanoma cell line BLM (BLM-tyr) did not affect the survival of this cell line. Right panel: the same cell panel was incubated for 72 hours in
the presence of H2O2, showing the protective effect of pigmentation on cell survival under oxidative stress.
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upregulated (Figure 3b), as well as the number of
HLA–DR-positive vesicles (Figure 3c), whereas early endo-
some antigen-1 expression was unaffected (Figure 3a).
Moreover, tyrosinase colocalized with LAMP1-positive
vesicles (arrowheads in magnification Figure 3b and c).
Furthermore, HLA–DR expression reached a maximum at
3 hours of exposure, revealing enhanced colocalization
between tyrosinase and HLA–DR-positive vesicles (arrow-
heads in magnification Figure 3c). These HLA–DR/tyrosinase-
positive vesicles were slightly larger organelles, suggestive of
multivesicular bodies characteristic of late-stage APs proces-
sing antigen for MHC class II presentation (Schmid et al.,
2007).
As the vitiligo-inducing effect of monobenzone is medi-
ated by topical exposure of the skin, we verified the effects
of monobenzone in human skin melanocytes. As shown in
Supplementary Figure S1A and S1B online, melanocytes also
initiated a lysosomal response on 1 hour of monobenzone
exposure, consisting of upregulation of LAMP1 and HLA–DR
expression, colocalizing with cytoplasmic tyrosinase (arrows
in magnification), whereas early endosome antigen-1 expres-
sion was unaffected.
As ubiquitination of protein aggregates can enhance
autophagy (Kirkin et al., 2009), besides providing antigen
for the MHC class I presentation route, we investigated
whether monobenzone induced ubiquitination of tyrosinase,
in particular during prolonged monobenzone exposure.
Unexposed melanoma cells analyzed by confocal laser
scanning microscopy displayed low ubiquitin expression
(Figure 4a). After 1 hour of monobenzone exposure, cellular
ubiquitin upregulation and foci of tyrosinase-associated
ubiquitination were observed (Figure 4a, arrows). Following
3 hours of monobenzone incubation, numerous small
foci and larger complexes were identified showing colocali-
zation of tyrosinase and ubiquitin (Figure 4a, arrowheads).
Western blot analysis of these exposed melanoma cells
indicated that monobenzone induced increased protein
ubiquitination (Figure 4b). The predominance of heavy
ubiquitinated proteins suggests polyubiquitination. Immuno-
precipitation of tyrosinase confirmed that tyrosinase was
subjected to (poly)ubiquitination following monobenzone
exposure. Increased ubiquitination was absent in mono-
benzone-treated tyrosinase-negative MCF7 control cells
(Figure 4b). Together, these results demonstrate that exposure
of pigmented cells to monobenzone induces tyrosinase
ubiquitination and the autophagocytic degradation of mela-
nosomes by means of lysosomal uptake and subsequent
fusion with HLA–DR-containing vesicles.
Monobenzone augments the release of tyrosinase- and
melanoma antigen recognized by T cells-1 (MART-1)-containing
exosomes by pigmented cells
As monobenzone may induce oxidative stress in pigmented
cells (Boissy and Manga, 2004), which can promote the
release of exosomes (Soderberg et al., 2007), we tested the
generation of ROS in a panel of monobenzone-exposed
pigmented cells and the tyrosinase-negative control MCF7
cell line. Monobenzone induced ROS in exposed melanoma
cells and melanocytes, whereas MCF7 cells displayed back-
ground levels of ROS during exposure (Figure 5a). Impor-
tantly, the induced ROS were not cytotoxic as monobenzone
was not selectively toxic to pigmented cells (Figure 1d).
Thereafter, we analyzed exosome release from pig-
mented cells exposed to monobenzone. Exosomes were
isolated from the culture supernatant by ultracentrifugation
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Figure 2. Monobenzone induces melanosome autophagy. Electron
microscopy analysis of pigmented human melanoma cells (92.2) exposed
to 20mM monobenzone for 3 hours. (a) Unexposed melanoma cells contain
all normal melanosome developmental stages, with typical cigar-like
morphology and the striations of stage II and III melanosomes. Scale bars
indicate 10 and 1mm. (b) On 60minutes of monobenzone exposure,
melanoma cells contained fewer stage IV melanosomes. Stage II and III
melanosomes appeared disorganized (arrows). Scale bars indicate 5 and
1mm. (c) Melanoma cells no longer contained stage IV melanosomes on
3hours of monobenzone exposure. Unmelanized stage III melanosomes (UM)
were visible. Double-membrane walled structures containing electron-dense
material were found, typical for melanin-containing autophagosomes (APs;
arrowheads for double membrane). APs fused with electron-lucent lysosome-
like structures (L; arrows for fusion), forming single-membrane-walled
autolysosomes (ALs). Data represent the results of two independent
experiments on two human pigmented melanoma cell lines (92.2 and 136.2).
Scale bars indicate 5 and 1 mm. N, nucleus.
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Figure 3. Lysosome-dependent melanosome degradation by monobenzone. Confocal laser scanning microscopy analysis of pigmented human melanoma
cells (92.2) exposed to 20 mM monobenzone. Tyrosinase (green) for melanosomes and 4
0
,6-diamidino-2-phenylindole (DAPI) for nucleus (blue). Glow over/under
panels (glow o/u) display fluorescence intensity of designated marker, indicating expression level from low (red/orange) to high (white/blue). Isotype
mAb control incubations were negative (iso panels). (a) Early endosome antigen-1 (EEA1; red) expression was not upregulated by 60minutes of exposure,
nor did tyrosinase colocalize with EEA1. Scale bar¼ 20mm for all panels. (b) Lysosome-associated membrane protein-1 expression (LAMP1; red)
was upregulated after 60minutes of exposure. Tyrosinase colocalized with lysosomes (arrowheads). Scale bar¼ 20mm for all panels. (c) Major
histocompatibility complex class II (HLA–DR; red) was upregulated after 60minutes of exposure, reaching maximum expression after 180minutes of
exposure. Thereafter, tyrosinase colocalized to HLA–DR-containing vesicles (arrowheads). Scale bar¼ 20 mm for 0minutes, and 8 mm for 60 and
180minutes. The data represent the results of two independent experiments on two pigmented human melanoma cell lines (92.2 and 136.2).
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(Savina et al., 2003) and identified by transmission electron
microscopy (Figure 5b). We analyzed the exosomes by their
adsorption on aldehyde/sulfate latex beads and flow cytometric
detection of specific antigens (Mathivanan and Simpson,
2009). Figure 5c shows that melanocytes or melanoma cells
release increasing number of exosomes when exposed to
monobenzone over time. These exosomes carried the CD63
exosome marker and tyrosinase and MART-1 antigens. In
contrast, MCF7 cells did not enhance exosome release follow-
ing monobenzone exposure, nor did its exosomes contain
DAPI Tyrosinase Ubiquitin Ubiquitin (glow o/u) Overlay Iso
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Monobenzone
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β-Actin
Figure 4. Enhanced tyrosinase ubiquitination following monobenzone exposure. (a) Confocal laser scanning microscopy analysis of pigmented human
melanoma cells (92.2) exposed to 20mM monobenzone. Staining with 4
0
,6-diamidino-2-phenylindole (DAPI) for nucleus (blue). Glow over/under panels
(glow o/u) show the fluorescence intensity of ubiquitin, indicating its expression level from low (red/orange) to high (white/blue). Upper row: low ubiquitin (red)
expression in untreated melanoma cells, only small ubiquitination complexes were present (arrows). Middle row: ubiquitin expression was upregulated on
60minutes of incubation, foci of tyrosinase-associated ubiquitination (arrows) were found. Lower row: after 180minutes of exposure, melanoma cells displayed
large complexes and small foci of tyrosinase/ubiquitin colocalization (arrowheads). Scale bar¼ 16mm for all panels. Isotype mAb control incubations were
negative (iso panel). Data represent the results of two independent experiments in two different melanoma cell lines (92.2 and 136.2). (b) Western blot analysis
of pigmented human melanoma cells (92.2) and tyrosinase-negative control cells (MCF7) exposed to 20 mM monobenzone for 2 hours. Analysis of whole-cell
lysate (input) showed that melanoma cells express the tyrosinase protein (Tyr), whereas MCF7 cells do not. Monobenzone treatment did not alter tyrosinase
expression level, but enhanced protein ubiquitination in the 92.2 cells. The predominance of heavy ubiquitinated proteins suggests polyubiquitination.
Immunoprecipitation of tyrosinase (IP tyrosinase) showed altered tyrosinase weight distribution and (poly)ubiquitination following monobenzone exposure.
Data represent the results of two independent experiments.
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tyrosinase or MART-1 antigen (data not shown). These data
demonstrate that monobenzone, by inducing cellular oxidative
stress, augments the release of melanocyte-differentiation
antigen-containing exosomes from exposed pigmented cells.
Monobenzone-exposed melanoma cells activate DCs
Next we investigated whether monobenzone-exposed mela-
noma cells induced DC activation. Supplementary Figure S2A
online shows immature DCs to express low levels of the
activation markers CD86 and HLA–DR. Expression of the
CD14 monocyte marker was negative (data not shown).
DCs were incubated with polyinosinic:polycytidylic acid
(poly I:C) to induce optimal DC maturation. Lysate of
monobenzone-exposed melanoma cells induced DC acti-
vation comparable to untreated melanoma cell lysate.
Interestingly, monobenzone-treated intact melanoma cells
induced DC activation, whereas monobenzone-treated
intact tyrosinase-negative Epstein-Barr virus (EBV)-B cells
did not. This demonstrates the dependence of the observed
DC activation on the interaction of monobenzone with
tyrosinase. Importantly, monobenzone did not disrupt mel-
anoma cells during overnight incubation (data not shown).
Control incubations of DCs with monobenzone, melanoma,
or EBV-B cells alone did not trigger DC activation (data not
shown).
To analyze the nature of this DC activation, we compared
the uptake of cell-derived matter from monobenzone-treated
and -untreated melanoma cells by DCs, using carboxy-
fluorescein succinimidyl ester (CFSE)-labeled melanoma cells.
CFSE fluorescently labels intracellular proteins covalently (Lyons
and Parish, 1994) and does not diffuse out of cells. CFSE-
labeled, thoroughly washed, melanoma cells were cocultured
with immature DCs for 3hours. Subsequently, uptake of CFSE-
labeled matter by DCs was analyzed by confocal laser scanning
microscopy. As Supplementary Figure S2B online shows,
control incubations with DCs alone showed CFSE-negative
DCs. DCs cocultured with intact CFSE-labeled melanoma
cells did not ingest any matter from these cells. In contrast,
monobenzone treatment of intact melanoma cells led to the
uptake of CFSE-positive matter by DCs. DCs had also taken up
CFSE-labeled debris from lysed melanoma cells, either mono-
benzone treated or unexposed. These results show that mono-
benzone exposure of melanoma cells triggers the release of
intracellular-derived antigenic matter, likely by the monoben-
zone-induced exosomes, which is readily taken up by DCs.
Monobenzone-exposed pigmented cells induce
melanoma-reactive CD8þ T cells within 7 days in vitro
On the basis of the observation that monobenzone induces
leukoderma, which can spread to non-exposed sites, we
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Figure 5. Monobenzone induces reactive oxygen species (ROS) and antigen-containing exosome release in pigmented cells. (a) Human melanocytes
(M0508A), human melanoma cells (92.2, 136.2, and WBO), and tyrosinase-negative MCF7 control cells were incubated with 20mM monobenzone for
90minutes. During exposure, ROS were formed in the pigmented cells. MCF7 cells display background levels of ROS on exposure. Data are normalized to the
ROS levels present in each cell line without monobenzone addition. (b) Transmission electron microscopy image of an exosome from the prepared culture
supernatants of melanoma cells treated with 20mM monobenzone for 3 hours (136.2 and 92.2). Data represent the results of two independent experiments.
Scale bar¼ 100nm. (c) Human melanocytes (M0508A), human melanoma cells (136.2 and 92.2), or tyrosinase-negative control cells (MCF7) were incubated
with 20mM monobenzone for 180minutes. During exposure, increasing numbers of tyrosinase- and MART-1 antigen-containing exosomes were released
by pigmented cells. In contrast, monobenzone did not induce exosome release from MCF7 cells. Released exosomes were found to express the exosome-specific
marker CD63. Data are normalized to the exosome release levels of untreated cells for each cell line. MART-1, melanoma antigen recognized by T cells-1.
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investigated the nature of this systemic reaction. In particular,
we studied whether monobenzone can induce CD8þ T-cell
reactivity to pigmented cells. Therefore, we performed a
series of cross-presentation experiments using monocyte-
derived DCs and autologous T cells from nine healthy human
donors. The DCs were loaded with either a freeze–thaw
melanoma cell lysate or with melanoma cells previously
exposed to monobenzone. Importantly, no DC-activating
stimuli were added to the cultures. The DCs were confirmed
to be immature before coculture (Supplementary Figure S2A
online upper row). Melanoma cell lysate is well suited to
prime tumor-antigen-specific T cells by DCs (Kotera et al.,
2001), and thereby functions as a reference stimulation.
Furthermore, it provides a representative source of melano-
ma-specific antigen to the DCs, as procedures such as UV- or
g-irradiation are known to significantly alter autoantigen
expression, processing, and surface presentation (Reits et al.,
2006).
Figure 6a depicts representative healthy donor DC–T-cell
stimulations. The columns designated ‘‘ex vivo’’ show that
CD8þ T cells from healthy donors did not ex vivo recognize
autologous DCs presenting melanoma cells exposed or
unexposed to monobenzone (both either lysed or intact).
On 7 days of coculture under these conditions and subse-
quent restimulation, a population of CD8þ T cells reactive
to DCs cross-presenting monobenzone-exposed melanoma
cell lysate had emerged, whereas DCs loaded with un-
exposed melanoma cell lysate (or intact cells) did not induce
T-cell activation. Strikingly, profound T-cell activation was
induced by DCs cross-presenting intact monobenzone-
exposed melanoma cells, illustrating that monobenzone
confers functional immunogenicity to intact pigmented
cells. Control stimulations neither revealed T-cell reactivity
against unloaded DCs, nor direct T-cell recognition of intact
melanoma cells (data not shown). Monobenzone-induced
T-cell activation was found in eight additional healthy human
donors as shown in Figure 6b. Here, significant activation
of CD8þ T cells reactive to 20mM monobenzone-exposed
intact melanoma cells was induced by day 7. Moreover,
melanoma cells exposed to 40mM monobenzone induced even
more CD8þ T-cell activation. Further increasing mono-
benzone exposure of melanoma cells did not enhance T-cell
reactivity (data not shown). In contrast, no T cells reactive to
untreated melanoma cells were found, indicating that mono-
benzone increased the immunogenicity of the melanoma cells.
To exclude melanoma cell alloreactivity induced by
monobenzone, we performed cross-presentation experiments
using the melanoma cell line mel-WBO and the autologous
EBV-transformed B-cell line EBV-WBO. The CD8þ T cells
activated by monobenzone-exposed mel-WBO during the 7-
day coculture did not respond to autologous EBV-WBO cells.
This shows that monobenzone-exposed melanoma cells did
not induce T-cell alloreactivity but selectively activated
melanoma-reactive T cells. Figure 6c shows that EBV-WBO
lysate did not induce a T-cell response, not even when these
cells were exposed to monobenzone before coculture.
Thereby monobenzone did not increase the immunogenicity
of these unpigmented cells.
As shown in Figure 6d, CD4þ T-cell activation was found
in all stimulation conditions of monobenzone-exposed and -
unexposed melanoma cells to equal degrees. These results
demonstrate that the monobenzone exposure of the melano-
ma cells selectively affected the generation of melanoma-
reactive CD8þ T cells. Taken together, these results
demonstrate that the interaction of monobenzone with
tyrosinase elevated the immunogenicity of melanoma cells,
resulting in the effective induction of a melanoma cell-
reactive CD8þ T-cell response.
Monobenzone-induced melanoma-reactive CD8þ T cells also
recognize unexposed melanoma cells
As monobenzone-induced vitiligo progressively spreads to
unexposed skin sites, we tested whether CD8þ T cells
induced by the monobenzone-exposed melanoma cells
could recognize both monobenzone-exposed and -unex-
posed melanoma cells. We cloned the activated T cells by
single-cell flow cytometry sorting of IFN-g-producing T cells,
following day 7 restimulation. CD8þ T-cell clones were
established from five healthy donor cultures. Shown in
Supplementary table S2 online, all T-cell clones recognized
autologous DCs loaded with intact monobenzone-exposed
melanoma cells. None of the T-cell clones recognized
unloaded DCs, or DCs loaded with MCF7 control cells,
indicating their melanoma-specific activation. Importantly,
seven out of nine clones (78%) equally recognized auto-
logous DCs loaded with either monobenzone-exposed or
-unexposed melanoma cells. Interestingly, two out of nine
T-cell clones were less reactive with monobenzone-untreated
melanoma cells (no. 3 and 9), one being unresponsive to
unexposed melanoma cells (no. 9). Possibly, these two clones
were reactive with an epitope containing a quinone-hapten,
an epitope absent from unexposed cells. Importantly, these
data provide immunological evidence for the clinical
observation that monobenzone-induced vitiligo eventually
spreads beyond the monobenzone application site to
unexposed skin areas, and illustrates that monobenzone
exposure of melanoma cells leads to the activation of a T-cell
response against antigens present on both monobenzone-
treated and -untreated melanoma cells.
DISCUSSION
The present study establishes how monobenzone induces
distinct immunological effects, which each contributes to
induce potent immunity specifically against pigmented
cells. First, we have shown that monobenzone inactivated
the tyrosinase pigment-synthesis enzyme, and that quinone-
haptens were formed to its cysteine residues by the
monobenzone metabolite 4-benzoxy-1,2-benzoquinone.
Monobenzone exposure reduced pigment-cell melanogen-
esis, without exerting selective toxicity toward these cells.
In addition, exclusively in pigmented cells, monobenzone
induced ROS, the release of tyrosinase- and MART-1-
containing exosomes, and melanosome autophagy. The
autophagocytic response was found to target melanosomal
tyrosinase protein via lysosomal degradation to MHC class II
compartments. Moreover, ubiquitination of tyrosinase protein
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was augmented upon monobenzone exposure. Strikingly,
intact monobenzone-exposed melanoma cells activated DCs
that had taken up matter from these cells. Subsequently, these
DCs induced a robust melanoma-reactive CD8þ T-cell
response within 7 days in vitro in nine healthy human donors.
The potency of monobenzone to induce such immune
responses was found to be pigment-cell-dependent and did
not represent alloreactivity.
Although autophagy can precede imminent cell apoptosis
under conditions of enduring stress (Hotchkiss et al., 2009),
the monobenzone-induced ROS was not toxic to the
pigmented cells. Autophagy has a clear relationship to the
generation of antigen for presentation in MHC class I and
class II molecules. MHC class II antigen-loading compart-
ments regularly receive antigen input from APs (Schmid et al.,
2007), while it also enhances endogenous antigen presenta-
tion in MHC class I (English et al., 2009). Importantly, the
observed exosomes may also result from the autophagy
process. Although macroautophagy degrades whole orga-
nelles, microautophagy engulfs small portions of cytoplasm,
possibly containing proteins released from damaged orga-
nelles such as tyrosinase and MART-1 (Mizushima, 2007).
This typically occurs via membrane invaginations of the
multivesicular endosome (Thery et al., 2009), a late
endosomal compartment, which thereby forms many cyto-
sol-containing vesicles that can eventually be released as
exosomes (Fevrier and Raposo, 2004). Collectively, mono-
benzone exposure of pigmented cells leads to the constant
engagement of exposed cells in the degradation, processing,
and presentation of melanosomal proteins. This enhanced
melanosomal antigen presentation can result in the priming
of autoreactive T cells, and provides the most likely
explanation for the elevated immunogenicity of monoben-
zone-exposed pigmented cells. Interestingly, melanocytes are
quite unique cells in the sense that they express MHC class II,
similar to DCs, and display effective antigen-presenting
capabilities (Le Poole et al., 1993). This implies that the
exposed melanocyte by itself can initiate melanocyte
antigen-specific T-cell immunity.
We also observed augmented tyrosinase (poly)ubiquitina-
tion in monobenzone-exposed cells, which suggests protein
ubiquitination in damaged melanosomes. Besides targeting
proteins to the MHC class I degradation route, ubiquitination
has a distinct role in autophagy. Ubiquitination of peptide
aggregates functions as a receptor for the initiation of
macroautophagy (Kirkin et al., 2009). Furthermore, ubiquiti-
nated transmembrane proteins, such as tyrosinase and
MART-1 in the melanosome, are directed to the vesicles of
the multivesicular endosome (Hicke, 2001). Thereby, active
shuttling of these proteins into the exosomal pathway may
be enhanced by monobenzone. Monobenzone-induced
exosomes were found to contain tyrosinase and MART-1
antigen. The active release of cell-specific antigen-containing
exosomes is a potent inducer of adaptive immunity (Zeelen-
berg et al., 2008). The tyrosinase protein in these exosomes
will carry quinone-haptens, whereas other proteins such as
MART-1 or gp100 are likely to be present in their native
form. The excretion of these antigens explains why mono-
benzone-exposed melanoma cells induce T cells to be
reactive to both monobenzone-exposed and -unexposed
melanoma cells.
Increased exosome secretion alone cannot account for
the observed DC activation by monobenzone-exposed mela-
noma cells. The quinone-haptens we observed can partly
explain this effect. In a recent study (Palm and Medzhitov,
2009), protein haptenation was found to overcome the
need for Toll-like receptor signaling in inducing immunity
against an otherwise non-immunogenic protein. Moreover,
contact-sensitizing compounds generating haptens such as
trinitro-chlorobenzene can activate DCs via triggering of the
NALP3 inflammasome (Yazdi et al., 2007). Furthermore, ROS
are known to induce adenosine triphosphate release from
tumor cells (Efferth and Oesch, 2004), which is a potent
metabolic danger stimulus activating the NALP3 inflamma-
some (Schroder et al., 2010). Thereby, it is possible that
monobenzone-exposed pigmented cells activate DCs in two
different ways: first, the generation of ROS may mediate
adenosine triphosphate release from exposed cells, stimulat-
ing activation of the NALP3 inflammasome in local DCs.
Second, DC uptake of quinone-haptenated tyrosinase-
containing exosomes may augment DC activation via
additional triggering of the NALP3 inflammasome.
In conclusion, we here show that conversion of mono-
benzone by the tyrosinase enzyme confers potent immuno-
genicity to pigmented cells by effectively integrating different
cellular and immunological processes. This, to our knowl-
edge previously unreported mechanism of monobenzone-
induced autoimmune vitiligo, provides the effectual basis for
Figure 6. Melanoma cells exposed to monobenzone prime melanoma-specific cytotoxic T cells. (a) Left panels: in vitro overnight T-cell stimulation ex vivo
with autologous dendritic cells (DCs) loaded with melanoma cells previously exposed overnight to 40 mm monobenzone or unexposed melanoma cells
(both either lysed or intact). CD8þ T cells were not activated by these conditions. Right panels: after 7 days of incubation, cultures were restimulated.
CD8þ T cells were reactive to DCs loaded with monobenzone-exposed melanoma cells (intact or as a lysate), whereas reactivity against DCs loaded with
monobenzone-untreated melanoma cells was absent. Intact monobenzone-exposed melanoma cells induced the most profound T-cell activation. (b) CD8þ
T-cell reactivity against 20 or 40mm monobenzone-exposed intact melanoma cells was found in nine healthy human donors. Graphs show T-cell activation
as IFN-g and TNF-a production by CD8þ T cells. Monobenzone-exposed melanoma cells increased CD8þ T-cell activation after 7 days of stimulation,
whereas monobenzone-unexposed melanoma cells did not. Data show the mean result of nine healthy donors. (c) The control Epstein-Barr virus (EBV)-
transformed B-cell line EBV-WBO did not induce CD8þ T-cell reactivity within 7 days, similar to monobenzone-treated EBV-WBO. CD8þ T cells induced
by the monobenzone-exposed melanoma cell line mel-WBO did not display alloreactivity to autologous EBV-WBO cells. Data show the mean result of
four healthy donors. (d) CD4þ T-cell activation was comparable to DCs incubated with either monobenzone-exposed or -unexposed melanoma cells.
Data represent the results of four independent experiments. NS, not significant (P40.05); *Po0.05, **Po0.01, using unpaired t-test (95% confidence interval)
in b and c, and paired t-test in d. Graphs depict mean with SEM.
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our successful and easily applicable monobenzone-imiquimod-
CpG therapy for melanoma, which we previously developed
in the B16-B6 model of murine melanoma (van den Boorn
et al., 2010). Taken together, monobenzone represents a
potent and innovative way of inducing potent immunity
against pigmented cells, with great promise to the field of
cancer immunotherapy.
MATERIALS AND METHODS
Spectrophotometric studies
Mushroom tyrosinase (Sigma-Aldrich, Steinheim, Germany) was
dissolved in 50mM phosphate buffer (pH 7.1). A volume of
10Uml1 tyrosinase was supplemented with either 250mM L-DOPA
(Fluka, Sigma-Aldrich) or 100 mM monobenzone (Sigma-Aldrich). For
complete inactivation of tyrosinase, 300 mM monobenzone was used.
Reactions were carried out in suprasil quartz cuvettes (Hellma,
Aartselaar, Belgium) at room temperature and oxygenized before
incubation by vortexing. At 2-minute intervals, the 250–550 nm
absorption spectrum was determined by a spectrophotometer
(V-560; Jasco, Great Dunmow, UK).
Peptide haptenation analysis
Synthesis of 4-benzoxy-1,2-benzoquinon: to an ice-cooled solution
of KH2PO4 (50mg) in water (25ml) was added Fremy’s salt
(potassium peroxylamine disulfonate, 500mg). The reaction mixture
was extracted with chloroform (3 25ml) and the collected organic
layers were dried on MgSO4. The solvent was evaporated in vacuo
after which the residue was used directly. Reaction of 9-mer peptides
with 4-benzoxy-1,2-benzoquinon: 5mM of peptide solution in a 9:1
mixture of 50mM phosphate-buffered saline, pH 7.2/acetonitrile,
total volume 250ml, was treated with (0–40 ml of a 0.25M stock
solution in acetonitrile) 4-benzoxy-1,2-benzoquinon. After 1 hour,
the reaction was quenched with 30 ml trifluoroacetic acid and the
mixture was analyzed by liquid chromatography–mass spectrometry
(reverse phase high performance liquid chromatography, 10–90%
gradient of acetonitrile). Quinone adduct was detected when MHþ
and MH2
2þ of the 4-benzoxy-1,2-benzoquinon-incubated peptides
showed an increase of 214.2 or 107.1, respectively, as compared
with starting material.
DC–T-cell autologous cocultures and restimulation
Peripheral blood mononuclear cells were obtained from blood
donated by healthy human subjects. Blood donation followed
approval by the ethical committee of the Academic Medical Center
(Amsterdam, the Netherlands). The present study was conducted
according to the Declaration of Helsinki Principles. DCs were
generated as described previously (de Jong et al., 2002). DCs were
cultured in 48-well plates at 105DC per well in 1ml IMDM (Life
Technologies, Carlsbad, CA) supplemented with GM-CSF (500Uml1,
Schering-Plough, Kenilworth, NJ), and were cocultured with 2 105
melanoma cells (1:1 mixture of melanoma cell lines mel-WBO and
mel-136.2, or mel-WBO alone) or EBV-WBO previously incubated
overnight with 0, 20, or 40 mM monobenzone in 100ml of IMDM per
2 105 cells at 37 1C 5% CO2. When required, melanoma cells were
lysed by 3 freeze–thawing using liquid N2 before DC loading.
After 6 hours, autologous peripheral blood mononuclear cells were
added to the DCs at 2 105 cells per well. peripheral blood
mononuclear cells were previously cultured for 7 days in IMDM
(PAA GmbH, Pasching, Austria) with 10% FBS (Hyclone, Cramlington,
UK), supplemented with 15 mgml1 gentamycin (Duchefa, Haarlem,
the Netherlands), 20Uml1 IL-2 (Novartis, Arnhem, the Netherlands),
and 5 ngml1 IL-15 (CLB/Sanquin, Amsterdam, the Netherlands).
IL-2, IL-15, and gentamycin were added to the DC–T coculture.
To test T-cell activation, Brefeldin-A was added (Golgiplug, 1:1000;
BD Biosciences, San Diego, CA) during overnight incubation to
allow determination of cytokine production by flow cytometry the
following day. Alternatively, the coculture was cultured for 7 days,
followed by an overnight restimulation and T-cell activation analysis.
Unloaded DCs and phorbol 12-myristate 13-acetate/ionomycine-
stimulated T cells were included as controls in the stimulations
(Leukocyte activation cocktail, 1:500, BD Biosciences).
Exosome isolation and analysis
Exosomes were isolated as described before (Mears et al., 2004), with
the modification of filtering supernatants at 0.2mm and centrifugation
of filtered supernatants at 100000 g. Flow cytometric analysis of
exosomes was performed using aldehyde/sulfate latex, 4% (w/v)
4mm beads (Invitrogen, Breda, The Netherlands), as described before
(Logozzi et al., 2009), using mAb specific for tyrosinase (clone T311,
1:200, Invitrogen), melanA (1:50, DAKO cytomation, Glostrup,
Denmark), and CD63 (1:100, BD Pharmingen, San Diego, CA).
mAb binding was detected by goat anti-mouse Alexa-488 for IgG2a-
isotype primary mAb (1:400, Invitrogen), and goat anti-mouse Cy3
for IgG1-isotype primary mAb (1:100, Jackson immunoresearch,
West Grove, PA). Exosome electron microscopy was performed as
described previously (Merendino et al., 2010).
Other assays
Cell culture, cellular melanin determination, cell survival assay,
electron microscopy, confocal microscopy analysis, immunopreci-
pitation, flow cytometry, and T-cell cloning by single-cell sorting
were carried out as described in the Supplementary Materials and
Methods section online.
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